ArticlePloS one2012
Determinants of recovery from severe posterior reversible encephalopathy syndrome.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02665598 (Prognostic Observation of Posterior Reversible Encephalopathy Syndrome), which is not on this map. Cited by 71 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Observation of Posterior Reversible Encephalopathy Syndrome
Who cites it
71 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk factors and outcomes of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a retrospective-multicentre cohort study and systematic literature review.Lupus science & medicine · 2025Pooled it
- Posterior reversible encephalopathy syndrome associated with antibiotic therapy: a case report and systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Frequency of ischaemic stroke and intracranial haemorrhage in patients with reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) - A systematic review.European journal of neurology · 2024Pooled it
- Analysis of Risk Factors Associated With Poor Outcome in Posterior Reversible Encephalopathy Syndrome After Treatment in Children: Systematic Review and Meta-Analysis.Frontiers in neurology · 2020Pooled it
- Multiterritory Acute Ischemic Stroke with Bilateral Middle Cerebellar Peduncle T2/FLAIR Hyperintensities in the Setting of a Fatal Systemic Arterial Thrombotic Process: A Case Report.Radiology case reports · 2026Article
- Article
- Article
- Posterior Reversible Encephalopathy Syndrome Potentially Associated With Erythropoietin Analogs: A Case Report.Cureus · 2025Article
- Posterior Reversible Leukoencephalopathy Syndrome and Disseminated Varicella-Zoster Virus Infection After Kidney Transplantation.IJU case reports · 2025Article
- Article
- Posterior reversible enzephalopathie syndrome (PRES) following vestibular schwannoma surgery - Case report and review of the current theories on pathophysiology of PRES.Brain & spine · 2025Review
- Malignant Hypertension Complicated by Posterior Reversible Encephalopathy Syndrome (PRES).Case reports in medicine · 2025Article
- Posterior Reversible Encephalopathy Syndrome Arising from Simultaneous Cranioplasty and Ventriculoperitoneal Shunting: A Case Report.NMC case report journal · 2025Article
- Severe Posterior Reversible Encephalopathy Syndrome Secondary to Hyponatremia in a Patient with Water Intoxication.The Neurohospitalist · 2024Article
- Pediatric Posterior Reversible Encephalopathy Syndrome: A Review With Emphasis on Neuroimaging Characteristics.Cureus · 2023Review
- Article
- Tonic-Clonic Seizure in Patient With SLE: Posterior Reversible Encephalopathy Syndrome, or a Neuropsychiatric Manifestation of SLE?Mediterranean journal of rheumatology · 2023Article
- Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis.Rheumatology and immunology research · 2023Article
- Article
- Long-term risk of seizure after posterior reversible encephalopathy syndrome.Annals of clinical and translational neurology · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFew outcome data are available about posterior reversible encephalopathy syndrome (PRES). We studied 90-day functional outcomes and their determinants in patients with severe PRES.
design70 patients with severe PRES admitted to 24 ICUs in 2001-2010 were included in a retrospective cohort study. The main outcome measure was a Glasgow Outcome Scale (GOS) of 5 (good recovery) on day 90. MAIN
resultsConsciousness impairment was the most common clinical sign, occurring in 66 (94%) patients. Clinical seizures occurred in 57 (81%) patients. Median mean arterial pressure was 122 (105-143) mmHg on scene. Cerebral imaging abnormalities were bilateral (93%) and predominated in the parietal (93%) and occipital (86%) white matter. Median number of brain areas involved was 4 (3-5). Imaging abnormalities resolved in 43 (88%) patients. Ischaemic and/or haemorrhagic complications occurred in 7 (14%) patients. The most common causes were drug toxicity (44%) and hypertensive encephalopathy (41%). On day 90, 11 (16%) patients had died, 26 (37%) had marked functional impairments (GOS, 2 to 4), and 33 (56%) had a good recovery (GOS, 5). Factors independently associated with GOS<5 were highest glycaemia on day 1 (OR, 1.22; 95%CI, 1.02-1.45, p = 0.03) and time to causative-factor control (OR, 3.3; 95%CI, 1.04-10.46, p = 0.04), whereas GOS = 5 was associated with toxaemia of pregnancy (preeclampsia/eclampsia) (OR, 0.06; 95%CI, 0.01-0.38, p = 0.003).
conclusionsBy day 90 after admission for severe PRES, 44% of survivors had severe functional impairments. Highest glycaemia on day 1 and time to causative-factor control were strong early predictors of outcomes, suggesting areas for improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.